

# Antimicrobial Resistance Profile of *Escherichia coli* Isolated from Raw Chicken Meat in a Selected Wet Market in Manila City, Philippines

Lyder Kyle A. Dimaapi, Angela Lorraine G. Dela Cruz, Roger Andrei D. Francisco, Rei Gilian D. Noble, Hayley Emerald G. Sabangan, Azita Racquel Gavino-Lacuna, RMT, MPH and Maria Margarita M. Lota, MD, MHPEd

*College of Public Health, University of the Philippines Manila*

## ABSTRACT

**Background and Objective:** Antimicrobial resistance (AMR) is a leading global public health concern as it resulted in more difficult-to-treat infections and fatalities. In the Philippines, drug-resistant *E. coli*, including multidrug-resistant (MDR), extended-spectrum beta-lactamase (ESBL)-producing, carbapenemase-producing carbapenem-resistant (CP-CR) *E. coli*, have been isolated from common food animals, increasing the risk of cross-contamination between humans, animals, and the environment. However, there is a lack of data on the distribution of *E. coli* in chicken meat in public wet markets. This study aims to describe the AMR profile of *E. coli* in raw chicken meat from retail stalls in a selected wet market in Manila City.

**Methods:** This quantitative descriptive study characterized the AMR profile of *E. coli* isolated from 25 raw chicken meat samples from a wet market in Manila City. Antimicrobial susceptibility was determined through disk diffusion method against 23 antimicrobial agents in 16 antimicrobial classes. MDR *E. coli* were identified based on the resistance patterns. ESBL- and carbapenemase-producing capacities of the bacteria were tested through double disk synergy test and modified carbapenem inactivation method, respectively.

**Results:** Twenty-four out of 25 (96%) chicken samples contained *E. coli* isolates. Of these, 23 (96%) were classified as MDR. High resistance rates were observed against ampicillin (92%), tetracycline (88%), trimethoprim-sulfamethoxazole (83%), chloramphenicol (79%), ampicillin-sulbactam (75%), amoxicillin-clavulanic acid (67%), fosfomicin (67%), and streptomycin (54%). The majority of the *E. coli* isolates were still susceptible to a wide range of selected antimicrobial agents, including carbapenems (100%), ceftriaxone (100%), cefepime (100%), cefuroxime (96%), cefotaxime (96%), ceftazidime (96%), piperacillin-tazobactam (96%), aztreonam (96%), ceftazidime (96%), piperacillin-tazobactam (96%), aztreonam (96%), ceftazidime (96%), and nitrofurantoin (83%), among others. Meanwhile, none of the 24 isolated *E. coli* samples were classified as ESBL- and CP-CR *E. coli*.

**Conclusion:** Among the 25 chicken samples, 24 *E. coli* colonies were isolated that exhibited 0% to 92% resistance rates against selected antimicrobial agents. Most isolates were classified as MDR, but none were considered ESBL- and CP-CR *E. coli*. This study suggests that chickens in wet markets can potentially serve as reservoir hosts for drug-resistance genes, which could transfer to other bacteria and contaminate humans, animals, and the environment within the food production and supply chain. These findings emphasize the need for AMR surveillance and strategies to combat AMR in the Philippines through the One Health approach.

**Keywords:** drug resistance, multi-drug resistance, ESBL, carbapenemase, *Escherichia coli*



Paper presentation – 2023 BSPH Student Research Colloquium, January 18, 2023, online via Zoom.

eISSN 2094-9278 (Online)  
Published: July 15, 2025  
<https://doi.org/10.47895/amp.vi0.8383>  
Copyright: The Author(s) 2025

Corresponding author: Lyder Kyle A. Dimaapi  
College of Public Health  
University of the Philippines Manila  
625 Pedro Gil St., Ermita, Manila 1000 Philippines  
Email: [ladimaapi1@up.edu.ph](mailto:ladimaapi1@up.edu.ph)  
ORCID: <https://orcid.org/0009-0003-5029-836X>

## INTRODUCTION

Antimicrobial resistance (AMR) is described as the phenomenon in which medicines are ineffective in inhibiting the growth and development of organisms due to specific modifications in the organisms' characteristics over time.<sup>1</sup> The proliferation of drug-resistant organisms has resulted in more difficult-to-treat infections and greater risks of severe hospital cases, disease transmission, and fatalities. The emergence and widespread distribution of these organisms urged the World Health Organization (WHO) to include AMR in the list of the leading global public health concerns affecting mankind.

AMR can be attributed to various mechanisms; one of which is through drug inactivation.<sup>2</sup> This mode of resistance is exemplified in extended-spectrum beta-lactamase (ESBL)-producing and carbapenemase-producing bacteria. ESBL-positive strains can produce enzymes capable of hydrolyzing beta-lactam-containing antibiotics such as penicillins and cephalosporins.<sup>3</sup> However, one notable limitation of ESBL-producing strains is that they are unable to metabolize cephamycins and carbapenems, which are then used to treat ESBL-related infections.<sup>4</sup> Meanwhile, the evolution of microorganisms has resulted in the emergence of carbapenemase-producing strains which manufacture carbapenemase enzymes that are able to inactivate carbapenems.<sup>5</sup> Studies have also observed that ESBL-producing and carbapenemase-producing carbapenem-resistant (CP-CR) organisms can exhibit horizontal gene transfer of ESBL and carbapenemase enzymes to other bacteria through plasmid-mediated mechanisms.<sup>6,7</sup>

Consequently, an increasing trend in the prevalence of multidrug-resistant (MDR), ESBL-producing, and carbapenem-resistant *Escherichia coli* isolated from both humans and animals has been reported across multiple countries.<sup>3,8-10</sup> The WHO has already classified carbapenem-resistant and ESBL-positive species of Enterobacteriaceae as Priority 1 or critical strains that are in need of urgent development of new and effective antibiotics.<sup>11</sup> Additionally, the Centers for Disease Control and Prevention (CDC) classified carbapenem-resistant and ESBL-producing Enterobacteriaceae under the categories "Urgent Threats" and "Serious Threats", respectively, to human health.<sup>12</sup>

Drug-resistant *E. coli* strains can infect animals, thereby increasing the risk of human infections through direct animal-human exposure or through the food chain and food supply.<sup>7,9</sup> Notably, these microorganisms are recognized as one of the primary pathogens associated with outbreaks of foodborne diseases worldwide that contribute to the significant rise in morbidity and mortality rates globally.<sup>1,3,7,9</sup>

In the Philippines, multiple reports have documented the widespread distribution of AMR *E. coli* in various settings. MDR *E. coli* have been detected in samples taken from slaughterhouses, livestock farms (e.g., poultry, buffalo, and swine farms), and raw chicken meat and animal-derived

food products from open markets and supermarkets across the country.<sup>13,14</sup> ESBL genes were also detected in selected small-scale urban agricultural farms. *E. coli* isolates collected from irrigation water, vegetable, and soil samples in Metro Manila, specifically in Quezon City, Marikina City, and Pasig City, were found to be positive for ESBL production.<sup>15</sup> ESBL-producing *E. coli* (ESBL-EC) have also been identified in poultry broiler farms across four provinces in the central region of Luzon.<sup>16</sup> In addition, a small percentage of the *E. coli* isolates from animal-related food products and swab-collected specimens from poultry farms, buffalo farms, swine farms, abattoirs, open markets, and supermarkets in the Philippines were observed to be resistant to carbapenems.<sup>14</sup> Carbapenem-resistant carbapenemase-producing *E. coli* (CP-CREC) have been detected as well in fish meat from Metro Manila wet markets.<sup>17</sup> The presence of carbapenem resistance genes was also identified from poultry broiler farm isolates in Central Luzon.<sup>16</sup> Despite these findings, there has been an observed lack of data on the distribution of drug-resistant bacteria in meat products in the Philippines. There are currently little to no available data on the contamination of MDR *E. coli*, ESBL-EC, and CP-CREC, specifically, from chicken meat in public markets in the country. As a result, limited knowledge is known regarding the impact of MDR *E. coli*, ESBL-EC, and CP-CREC in the transmission of drug-resistant pathogenic bacteria from chicken meat products in wet markets.

Considering the detection of these drug-resistant bacteria in livestock production and supply, there is an increased threat of transmission in public markets where bacteria can easily be spread among different food products and individuals. Hence, constant surveillance of ESBL-EC and carbapenem-resistant *E. coli* is critical in indicating the status of AMR evolution in the country.

This study, therefore, aimed to describe the AMR profile of *E. coli* in raw chicken meat from retail stalls in a selected wet market in Manila City. Specifically, this research aimed to characterize the susceptibility of isolated *E. coli* against selected antimicrobial agents and describe the antimicrobial resistance patterns (i.e., MDR, ESBL-producing, carbapenemase-producing) of isolated *E. coli* in raw chicken meat through absolute counts and proportions.

The detection and characterization of the AMR profile of *E. coli* in raw chicken meat in a selected wet market in Manila City could provide baseline information, which could later be utilized for the surveillance of AMR in the Philippines.

## MATERIALS AND METHODS

### Research Design

The study utilized a quantitative descriptive cross-sectional research design to characterize the AMR profile and antimicrobial resistance patterns of *E. coli* isolated from raw chicken meat from a selected wet market in Manila City.

## Study Area

The raw chicken meat samples were bought from retail stalls in a selected wet market located in Manila City. The selection of the study site was primarily due to the population density of Manila City as it was known as the most densely populated city among the Highly Urbanized Cities (HUC) in the National Capital Region (NCR) with a population density of 73,920 persons per square kilometer in 2020.<sup>18</sup> The feasibility and logistics concerns of the researchers were also considered in choosing the study site. Due to ethical considerations, the exact location of the wet market was not disclosed.

## Study Population

The study population consisted of retail stalls located within the selected wet market that sold raw chicken meat. There was a one-to-one correspondence between the stall and raw chicken meat as only one chicken sample was obtained from each selected retail stall.

## Inclusion Criteria

Retail stalls that sold raw chicken leg meat within the selected wet market in Manila City were included in the study. The stalls were located along the boundary streets or within the halls of the wet market. These stalls also sold chicken legs that were already cut from the chicken body prior to buying.

## Exclusion Criteria

Hung chicken legs or those already placed in plastic containers were not selected for this research. This exclusion criterion controlled and minimized the effects of environmental exposure as a confounding variable to the detection of AMR *E. coli*.

## Sampling Design

This study employed a probability sampling design in selected retail stalls selling chicken leg meat products. Specifically, the study site was divided into three areas to avoid duplication of selected stalls, and simple random sampling was performed in each location per collection batch to select chicken retail stalls. For chicken meat collection, convenience sampling was conducted wherein one raw chicken leg sample was collected from each retail stall. Then, specimen sampling was employed from each chicken leg sample for homogenization and bacteria isolation.

## Sample Size

Considering the financial resources, 25 stalls were included in this study. In each stall, one raw chicken meat was obtained; therefore, a total of 25 raw chicken samples were tested.

## Preparation, Collection, and Assay Procedures

The processes in describing the AMR profile of *E. coli* from chicken samples were (1) preparation of media, (2)

sample collection, (3) homogenization, (4) isolation of *E. coli*, (5) identification of *E. coli*, (6) antimicrobial susceptibility testing, (7) ESBL production screening and confirmation, (8) carbapenemase production screening and confirmation, and (9) data analysis.

## Preparation of Media

The media used in the study were MAC agar, EMB agar, Brain Heart Infusion (BHI) Broth, MHA, Triple Sugar Iron (TSI) slant, and nutrient agar slant.

These media were prepared under the guidance of personnel from the Department of Medical Microbiology (DMM) at the College of Public Health University of the Philippines Manila. Expiration dates and the quality of the materials were thoroughly ensured prior to creation. The procedure for the procurement of the media was strictly aligned with the standard instructions, and every step was constantly monitored by the personnel.

Biosafety measures were followed throughout the duration of the process to avoid contamination and to assure the excellent quality of the media. In cases of defective media, these were not utilized and were properly disposed of.

Quality control organisms were used in ensuring the accuracy of the media for supporting or inhibiting the growth of bacteria. Expected results were based on the growth and inhibition properties in line with proper morphological characteristics, and production of biochemical reactions. All media used *E. coli* ATCC 25922 for positive control.

## Sample Collection

Raw chicken leg meat, specifically the drumstick part, was collected from each of the 25 stalls in a selected wet market in Manila City. Chicken legs were selected as the study sample due to the high isolation rates of drug-resistant *E. coli* in whole legs and drumstick portions of the chicken.<sup>13,19</sup> The stall owners were not informed regarding the purpose of buying the chicken samples to eliminate the effects of demand bias by providing chicken samples that are less likely to have been exposed to conditions associated with AMR. The collection of chicken specimens began in September 2022, with three batches bought within the span of 2-3 weeks at around 7:00 to 8:00 in the morning. Five samples were collected in the first batch, and 10 samples in each succeeding batch. After buying the raw chicken meat, the sample was placed in separate sterile plastic bags and stored in an ice-filled cooler. The specimens were transported within five hours to the DMM Laboratory at the College of Public Health University of the Philippines Manila.

## Homogenization

Each meat sample was homogenized prior to isolation and identification of *E. coli*. About 25 grams of chicken meat were cut into very small pieces using aseptic techniques. These were placed inside a second sterile bag containing 225 mL of peptone water and vigorously shaken before being

mixed using a homogenizer for one minute. About 5 mL of each homogenized sample was transferred to a sterile bottle containing 45 mL of peptone water and mixed gently to create a mixture of the processed chicken meat sample. The resulting solution was then incubated at 37°C for 18 to 24 hours.<sup>14,19,20</sup>

### Isolation and Identification of *E. coli*

After incubation of the processed chicken meat sample, two sets of triplicates of 10- $\mu$ L loopful of the sample were simultaneously prepared. One set was streaked and subcultured onto MAC agar and the other set on EMB agar. The plates were incubated at 37°C for 18 to 24 hours. The colonies with pink coloration and metallic green sheen on MAC and EMB agar, respectively, were considered presumptive *E. coli* isolates and were subjected to phenotypic identity confirmation.<sup>21</sup> Identification of *E. coli* from each set-up was conducted using morphological and biochemical techniques, specifically, gram staining, IMViC, oxidase, and triple sugar iron (TSI) tests. Gram-negative rods bacteria with a negative oxidase test; a positive, positive, negative, negative (++) IMViC test; and a yellow slant yellow butt (A/A) which indicates glucose and lactose fermentation along with positive gas production and negative hydrogen sulfide production for the TSI test were considered positive of *E. coli*.<sup>21-23</sup> All tests were performed using a positive control of *E. coli* ATCC 25922.

Isolates that had inconsistent results in the morphological and biochemical tests underwent identification VITEK<sup>®</sup> MS in the Microbiology section of the Department of Laboratories, Philippine General Hospital (PGH), University of the Philippines Manila. This automated method uses Matrix-Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) technology in the determination of microorganisms.

Only one confirmed *E. coli* colony from the triplicate set-ups was randomly selected to proceed to the characterization of the AMR profile. These colonies were maintained on nutrient agar for storage at 4°C.<sup>24</sup>

### Antimicrobial Susceptibility Test

Selected *E. coli* isolates underwent antimicrobial susceptibility testing according to the CLSI's Kirby-Bauer disk diffusion susceptibility test protocol.<sup>25</sup> The antimicrobial susceptibility test consists of multiple steps, presented in order starting from inoculum preparation, inoculation to MHA, the addition of antimicrobial disks, incubation, measurement of inhibition zones, and interpretation of inhibition zones according to the CLSI standard protocol.

Stored *E. coli* from the nutrient agar were cultured in BHI broth and incubated overnight prior to inoculum preparation. To prepare the inoculum standard, isolated colonies of *E. coli* from the BHI broth were picked up by a sterile inoculating loop and placed into a test tube with 5 mL of sterile saline solution. The tube was then vortexed to mix the solution. Depending on the turbidity of the solution, the inoculum

density was adjusted to the 0.5 McFarland standard. In cases of a light suspension, organisms were added into the tube, while in a heavy suspension, it was diluted with sterile saline solution to achieve the standard equivalent. The prepared 0.5 McFarland standard was used to finally confirm the resulting suspension. Within 15 minutes of preparation, the confirmed inoculum was inoculated onto the MHA.

A sterile cotton swab was dipped in the tube containing the inoculum and rotated on the test tube side above the fluid level to remove excess fluid. The bacteria on the cotton swab were inoculated onto the MHA by streaking the swab three times in a back-and-forth motion across the entire surface while rotating the plate 60 degrees between each pass. Afterwards, the rim of the MHA plate was also swabbed. The plate was left for three to five minutes with the lid slightly ajar to allow the surface of the agar plate to dry prior to adding the antimicrobial disks.

The antimicrobial susceptibility was determined using the disk diffusion assay with 23 antimicrobial agents belonging to 16 antimicrobial classes as summarized in Table 1.

The antimicrobial-impregnated disks were pressed gently onto the surface of the MHA using sterile forceps. Each plate contained five antimicrobial disks placed at a minimum distance of 24 mm apart. All antimicrobial disks were tested against a control organism of *E. coli* ATCC 25922.

Within 15 minutes of adding the antimicrobial disks, the plates were stacked upside down, with no more than five plates on top of each other, and kept at 37°C for 18 to 24 hours.

After incubation, ZOI was measured to the nearest millimeter using a ruler or caliper. All measurements were made by observing the backs of the dishes with the naked eye. The diameter of the ZOI from edge to edge across the disk's center was measured using reflected light while holding the plate a few inches above a non-reflective background. Whenever there is an overlapping ZOI, the radius was used to measure the ZOI of a particular antimicrobial agent.

The CLSI guidelines for Enterobacteriaceae were used to interpret the ZOIs of the tested antimicrobials into three categories: susceptible, intermediate, and resistant.

### ESBL-EC Detection

*E. coli* isolates tested for ESBL production were initially screened through the use of antimicrobial susceptibility testing to cefotaxime, ceftriaxone, ceftazidime, and aztreonam. Results from previous AST of antibiotic disks were used. Isolates with ZOI of  $\leq 27$  mm for cefotaxime,  $\leq 25$  mm for ceftriaxone,  $\leq 22$  mm for ceftazidime, or  $\leq 27$  mm for aztreonam were further subjected to DDST. Prior to the confirmatory DDST, sample strains of *E. coli* from the nutrient agar were used to create a new set of inoculum. Similar protocols were applied from the previous AST inoculum preparation and inoculation to MHA for the preparation of media with the lawned organisms.

**Table 1.** Antimicrobial Disks Used Against the Isolated *E. coli*

Antimicrobial Classes	Antimicrobial Agents	Disk Content
<i>Aminoglycosides</i>	Streptomycin (STR)	10 µg
<i>Antipseudomonal Penicillin with beta-lactamase inhibitors</i>	Piperacillin-Tazobactam (TZP)	100/10 µg
<i>Carbapenems</i>	Ertapenem (ETP)	10 µg
	Imipenem (IPM)	10 µg
	Meropenem (MEM)	10 µg
<i>Non-extended spectrum cephalosporins</i>	Cefazolin (CFZ)	30 µg
	Cefuroxime (CXM)	30 µg
<i>Extended-spectrum cephalosporins</i>	Cefotaxime (CTX)	30 µg
	Ceftriaxone (CRO)	30 µg
	Ceftazidime (CAZ)	30 µg
	Cefepime (FEP)	30 µg
<i>Cephameycins</i>	Cefoxitin (FOX)	30 µg
<i>Fluoroquinolones</i>	Ciprofloxacin (CIP)	5 µg
<i>Quinolone</i>	Nalidixic acid (NAL)	30 µg
<i>Folate pathway inhibitors</i>	Trimethoprim-sulfamethoxazole (SXT)	1.25/23.75 µg
<i>Monobactams</i>	Aztreonam (ATM)	30 µg
<i>Penicillins</i>	Ampicillin (AMP)	10 µg
<i>Penicillins with beta-lactamase inhibitors</i>	Amoxicillin-clavulanic acid (AMC)	20/10 µg
	Ampicillin-sulbactam (SAM)	10/10 µg
<i>Phenicol</i>	Chloramphenicol (CHL)	30 µg
<i>Phosphonic acids</i>	Fosfomycin (FOF)	200 µg
<i>Tetracyclines</i>	Tetracycline (TET)	30 µg
<i>Nitrofurantoin</i>	Nitrofurantoin (NIT)	300 µg

The disks used for the MHA were amoxicillin-clavulanic acid (20 µg/10 µg) placed at the center of the MHA plate, three disks of third-generation cephalosporins [i.e., cefotaxime (30 µg), ceftriaxone (30 µg), and ceftazidime (30 µg)], and one-fourth generation cephalosporin [i.e., cefepime (50 µg)] placed with equal spaces of 15 mm and 20 mm from the center disk, respectively.<sup>26</sup> After adding the disks, the MHA plate was inverted and incubated for 18-24 hours at around 35°C ± 2°C. Positive results were indicated by distortions or increased extensions in the intersection of ZOI between the amoxicillin-clavulanic acid and cephalosporins.<sup>27</sup> Positive and negative quality control organisms were used to check the validity of the results.

### CP-CREC Detection

Isolates that underwent confirmatory tests for carbapenemase production were initially screened through the AST. All intermediate and resistant colonies to at least one carbapenem—imipenem (i.e., ZOI of ≤ 22 mm), meropenem (i.e., ZOI of ≤ 22 mm), or ertapenem (i.e., ZOI of ≤ 21 mm)—were subjected to confirmatory testing of carbapenemase production using mCIM.<sup>28</sup>

Stored *E. coli* were cultured in BHI broth. One microliter loopful of each isolate from the BHI broth was aseptically transferred into a test tube with 2 mL TSB. The tube was vortexed for 10-15 seconds. With sterile forceps, a 10-µg

meropenem disk was totally immersed into each test tube. All set-ups were incubated for 4 hours ± 15 minutes at around 35°C ± 2°C. Prior to the end of the incubation period, a 0.5 McFarland suspension of *E. coli* ATCC 25922 was inoculated onto an MHA dish within 15 minutes. Upon completion of the incubation, the meropenem disk was removed from the tube with the use of a 10-µL loop—the disk was pulled out through surface tension by positioning the flat part of the inoculating loop against the flat portion of the antimicrobial disk and then dragging and pressing the loop on the tube edge to remove excess fluid from the disk. Ensuring that the plates were air-dried for around 3-10 minutes, the meropenem disk was positioned on the MHA plate lawned with *E. coli* ATCC 25922. The agar was inverted and incubated for 18-24 hours at around 35°C ± 2°C. After incubation, ZOI was measured and interpreted using the CLSI standards.<sup>28</sup> ZOI of 6-15 mm or the growth of pinpoint colonies within the disk diameter of 16-18 mm was indicative of carbapenemase-producing *E. coli*. Carbapenemase-negative colonies were characterized by a clear ZOI of at least 19 mm. Meanwhile, indeterminate organisms for carbapenemase production were those with ZOIs of 16-18 mm or with growth of pinpoint colonies within a ZOI of at least 19 mm.<sup>28</sup> Positive and negative quality control organisms for mCIM were used to check for the validity of the results.

**Data Processing and Analysis**

*E. coli* isolates were labeled using specific codes to represent the stall source (letter codes) and bacteria number (number codes).

Descriptive statistical analysis was implemented to characterize the susceptibility of *E. coli* from raw chicken meat against selected antimicrobial agents and to describe their AMR patterns. Specifically, absolute counts and proportions were calculated, tabulated, and presented as shown in the appendices. A susceptible result suggested that the antimicrobial agent is effective against *E. coli*. An intermediate result implied that its effects on *E. coli* have an uncertain therapeutic impact, thereby requiring an increased dose. A resistant result suggested that the effect of the antimicrobial agent was not reliable to treat *E. coli*. Breakpoint values for the susceptibility of *E. coli* to each antimicrobial agent were detailed in Appendix Table 1. Meanwhile, resistance patterns refer to AMR classification (i.e., MDR or nMDR), and ESBL-producing and carbapenemase-producing characteristics of the isolates.

**Ethical Considerations**

The protocol of this research study requested and was approved for exemption from an ethical review of the Research Ethics Board (REB). Nonetheless, the framework of this study was performed in compliance with the ethical

guidelines stipulated in the National Ethical Guidelines for Health and Health-Related Research 2017.

**RESULTS**

**Presence of AMR *E. coli* in Raw Chicken Meat**

All 25 raw chicken meat samples were processed and subcultured on MAC and EMB agar plates. Samples that yielded green metallic sheen colonies on the EMB agar plates were subjected to morphological and biochemical testing. Among the 25 samples, 17 (68%) were confirmed to be presumptive *E. coli* isolates. The remaining 8 (32%) isolates with inconsistent biochemical tests underwent microbial identification through VITEK® MS, which uses MALDI-TOF technology. This automated process was able to provide data regarding the identification and antimicrobial susceptibility profile of bacteria and fungi. Among the 8 isolates, 7 were confirmed to be *E. coli*, while one was identified as *Citrobacter freundii*. In total, 24 of the 25 (96%) chicken samples contained *E. coli* isolates.

**Antimicrobial Susceptibility Profile of *E. coli* Isolates**

The study characterized the susceptibility of 24 *E. coli* isolates against 23 selected antimicrobial agents as shown in Figure 1 (see Appendix Table 2 for detailed proportions). Notably, high resistance rates were observed against ampicillin




Figure 1. Proportion of Susceptible, Intermediate, and Resistant *E. coli* isolated from raw chicken meat samples (n = 24).



grocery stores.<sup>20,37</sup> These data reinforce the need to address the widespread public health issue of AMR, both locally and globally.

### Antimicrobial Susceptibility Profile

The present study observed significantly high resistance rates to various antimicrobial agents, including ampicillin, tetracycline, trimethoprim-sulfamethoxazole, chloramphenicol, ampicillin-sulbactam, amoxicillin-clavulanic acid, fosfomycin, streptomycin, ciprofloxacin, and nalidixic acid against the isolated *E. coli* from raw chicken meat. These findings are aligned with the global findings of *E. coli* resistance rates against tetracycline (60% - 91.8%), trimethoprim-sulfamethoxazole (49.4% - 84%), nalidixic acid (53.4% - 74.1%), ampicillin (34% - 72.9%), and amoxicillin-clavulanic acid (69%) detected from raw chickens in different wet markets.<sup>38-44</sup> Similar results were also reported in previous research conducted in Quezon City, Philippines wherein there was a 100% resistance rate to ampicillin and an 88% resistance rate to tetracycline from raw chicken legs in a public wet market.<sup>13</sup> Additionally, a local study also found resistance rates to tetracycline at 58.33% and trimethoprim-sulfamethoxazole at 41.67% for chicken samples obtained in selected wet markets of Manila.<sup>45</sup> Resistance to tetracycline (66.1%), ampicillin (63.8%), trimethoprim-sulfamethoxazole (46.4%), nalidixic acid (45.1%), streptomycin (41.1%), and chloramphenicol (38.4%) against *E. coli* were also observed from chicken samples bought at abattoirs, supermarkets, open markets, and poultry farms across the Philippines.<sup>14</sup>

One of the factors that might have contributed to the presence of AMR bacteria in chicken meat could be the widespread use of antimicrobials in livestock farms. Evidence suggests that the use and misuse of antimicrobial agents in poultry farms of low- and middle-income countries (LMICs) is rampant for the rapid growth of healthier poultry animals.<sup>46</sup> Among commercial and backyard poultry farms in the four regions of the Philippines (i.e., Central Luzon, South Luzon, Central Visayas, and Western Visayas), 20% of broiler farms and 42% of layer farms are using three to four antimicrobial agents, while 100% of both broiler and layer farms utilize one to two antimicrobial agents for feed additives as well as for the treatment of respiratory and enteric diseases.<sup>46</sup> Additionally, commercial broiler farms in the Philippines have been using antimicrobials for metaphylaxis, prophylaxis, and growth promotion.<sup>47</sup> Consequently, antimicrobial susceptibility profiles of *E. coli* isolates from different chicken resource samples from poultry farms have shown increased resistance rates against these commonly-used antimicrobial agents. *E. coli* isolates from chickens in broiler farms in CALABARZON have also exhibited high resistance rates to nalidixic acid (97.5%), ampicillin (90%), ciprofloxacin (85%), tetracycline (80%), streptomycin (72.5%), trimethoprim (62.5%), and trimethoprim-sulfamethoxazole (62.5%).<sup>36</sup> These data suggest that AMR *E. coli* from chickens in wet markets might be due to the use of antimicrobials in poultry farms.

In this study, the highest resistance rate was seen in ampicillin (92%). This might be attributed to cross-resistance with antimicrobials in the same class, specifically with its analog, amoxicillin.<sup>48</sup> Amoxicillin is known to be used in broilers in the Philippines for prophylactic and treatment purposes.<sup>36,46</sup> A study also showed that chicks treated with amoxicillin during their growing period resulted in increased resistance rates of *E. coli* isolates to both amoxicillin and ampicillin<sup>49</sup>, thus suggesting the possibility of cross-resistance and co-resistance within the two agents.

It was also observed that tetracyclines, fluoroquinolones, quinolones, fosfomycin, and aminoglycosides are commonly used antimicrobials in poultry farms in the Philippines.<sup>45-47</sup> Resistance to these agents, as reported in this study, might be due to their uses as a growth promoter, prophylactic drug, and therapeutic medication for animals.<sup>41,45-47</sup> These findings are concerning considering that fluoroquinolones and quinolones are commonly used as first-line treatment against human foodborne infections caused by *E. coli* and *Salmonella*.<sup>50</sup>

Notably, studies have suggested the possibility of co-resistance to streptomycin and trimethoprim-sulfamethoxazole.<sup>36,51</sup> This co-resistance was identified in *E. coli* from meat products in Norway. It was reported that plasmids commonly harbor both *strA/strB* genes, which encode for streptomycin resistance and *sul2* genes for sulfonamide resistance, implying the presence of co-resistance to these two antimicrobials. The present study also identified 12 isolates that are co-resistant to both streptomycin and trimethoprim-sulfamethoxazole.<sup>51</sup> Another common co-resistance pattern evident in the local setting is the ampicillin-tetracycline-trimethoprim-sulfamethoxazole drug combination.<sup>14,36,45</sup> This study also found 17 isolates with this co-resistance pattern. This might be due to the unregulated use of these antimicrobial agents in Philippine poultry farms.<sup>46</sup>

Meanwhile, this study also exhibited findings inconsistent with existing literature. While this research found a high resistance rate to chloramphenicol at 79%, three local studies have detected much lower rates at 6.67%, 8%, and 38.4%.<sup>13,14,45</sup> The findings of this study are significant considering that chloramphenicol has been banned for usage among food-producing animals in the Philippines since 1990.<sup>52</sup> Potential causes of chloramphenicol resistance might be due to cross-resistance with antimicrobials within the same family or co-resistance with other antimicrobial classes as well as the illegal use of this agent in the agriculture industry.<sup>36</sup>

Aside from chloramphenicol, one study conducted in the Philippines also reported high resistance rates for non-extended- and extended-spectrum cephalosporins<sup>36</sup>, which are contrary to the findings of this study. Although there are no reports of cephalosporin use in local poultry farms, it was found that cephalosporins are used in local commercialized swine farms.<sup>46</sup> A probable reason for this unique finding is through cross-contamination with other animals and animal products.



Essentially, these data on AMR *E. coli* in the poultry industry suggest that the food production and supply chain can serve as a reservoir for drug-resistant genes that can be transferred to other animals and humans. In the clinical setting, the 2021 DOH-ARSP reported a comparable antimicrobial susceptibility profile of *E. coli* from clinical samples with the profile of this study.<sup>53</sup> Based on the DOH-ARSP report, percent resistance rates to the following antimicrobials are 78.7% to ampicillin, 54.8% to tetracycline, 54.5% to co-trimoxazole/trimethoprim-sulfamethoxazole, 48.5% to ciprofloxacin, and 45.9% to cefazolin. AMR bacteria can cross into the human population through direct contact with contaminated live animals and consumption of contaminated food products, or indirectly through the surrounding environment.<sup>54</sup> Considering these findings, strict surveillance and re-aligning of policies on the usage of antimicrobial agents in livestock farms must be prioritized to prevent further worsening of antimicrobial resistance.

### Multi-drug Resistant *E. coli*

This study identified 95.83% (23/24) MDR *E. coli* isolates from raw chicken meat samples. This high prevalence coincides with the findings in varying local wet markets ranging from 67.9% - 100% MDR *E. coli*.<sup>13,14</sup> In addition to these, international studies are also aligned with high rates of MDR *E. coli*. Other countries reported the following MDR *E. coli* rates from raw chicken in markets – China with 83.9%, Indonesia with 61.08%, Bangladesh with 76%, Zambia with 55%, and Qatar with 63.4%, among others.<sup>38,41-44</sup> This implies the continuous spread of antimicrobial resistance, specifically MDR *E. coli*, across the globe.

The identified increased MDR *E. coli* rates from chickens in wet markets are also similar to the rates observed in poultry farms in the Philippines. Two studies found prevalence rates of 92.5% and 95.65% of MDR *E. coli* isolated from freshly slaughtered chicken in broiler farms.<sup>16,36</sup> The variety of antimicrobial agents used in different farms across regions creates a wide extent of AMR problems with different scopes as both found locally and internationally.<sup>38,46</sup> Additionally, the demand to produce livestock, specifically chicken, calls for a greater number, larger dosage, frequent, and longer use of antimicrobials, which contributes significantly to MDR development.<sup>38</sup> The high demand for animal products in the Philippines increases the possibility of cross-contamination of MDR bacteria among animals, animal products, and humans.<sup>14</sup>

Environmental factors that affect the spread of MDR *E. coli* in chicken from wet markets include cross-contamination in different stages of production. In market settings, it was observed that the sewage samples from cleaning wholesale chicken meat in markets of Dhaka City in Bangladesh contain MDR *E. coli* with a prevalence of around 80%; higher MDR rates were also recorded in other bacteria.<sup>19</sup> These findings show the possibility of contamination among food products in the market. Therefore, hygiene practices should be given importance from the production site up to the markets.

### ESBL-producing *E. coli*

Out of the 24 *E. coli* isolates examined in this study, none were considered ESBL-producers. This finding is consistent with a local study conducted in Manila City, which reported 0% ESBL-positive *E. coli* among intestinal samples from chickens, pigs, and Nile tilapia sourced from wet markets.<sup>45</sup> This similarity may be attributed to the comparable sampling and environmental conditions considering that both studies utilized meat samples sourced from wet markets in Manila City. It can also be inferred that ESBL genes have not yet been transmitted among *E. coli* in chicken meat obtained in the selected wet market. However, there may also be a possibility of failure in detecting ESBL production as it has been established that phenotypic confirmatory tests are unable to exhibit all kinds of ESBL enzymes as compared with automated and genotypic methods.<sup>55</sup>

However, other studies reported significantly higher ESBL-EC rates. One research identified 52.82% ESBL-EC among various samples (i.e., chicken, pork, and beef) from multiple sources including abattoirs, wet markets, supermarkets, and livestock farms across the Philippines.<sup>56</sup> Additionally, another study detected 60.26% ESBL-positive *E. coli* strains from chickens in farms located in Central Luzon.<sup>16</sup> These significant differences in ESBL-positivity rates from the current study may be due to the greater sample sizes, wider sampling areas, therefore, chickens came from different sources with varying environmental conditions, and the type of samples (i.e., environmental swabs, cloacal swabs, and raw meat samples) used in the two studies.

Multiple studies have also identified possible sources of ESBL-EC in the Philippines. It was observed that surface waters used for irrigation systems in agricultural settings in Metro Manila were contaminated with ESBL-EC.<sup>15</sup> ESBL-positive strains of *E. coli* were also detected among tilapia samples from two wet markets in Manila City.<sup>17</sup> The presence of ESBL isolates in these settings may result in cross-contamination of pathogenic bacteria among animals, the environment, and humans, including the food production and supply chain. Therefore, despite the zero positivity rate observed in this study, continuous monitoring of ESBL-EC among poultry samples in wet markets should still be carried out as ESBL-resistance genes can be transferred from *E. coli* in poultry to humans or vice-versa through conjugative plasmids while harboring other antimicrobial resistance genes.<sup>57</sup>

Moreover, the positivity rates of ESBL internationally and in clinical samples locally are increasing. Although ESBL-positivity rates from chicken cloacal swabs in Indonesian markets remain low at 3.33% (2/60)<sup>58</sup>, some countries recorded relatively higher ESBL-positivity rates such as 14.49% in Egypt, 39.2% in Peru, 53% in Cambodia, 53.8% in Malaysia, 76.8% in the Netherlands, and 86% in Bangladesh.<sup>19,20,59-62</sup> Researchers have suggested that travelers, especially those coming from Southeast Asia and India, contribute largely to the spread of ESBL-positive strains

to other countries.<sup>63</sup> Hence, the high rates of ESBL-EC in poultry production in other areas can potentially affect the ESBL-EC rates in the Philippines. The DOH-ARSP also published in its 2021 annual report an ESBL-EC-positivity rate of 24.51%, in addition to the 29.53% ESBL-positivity among *K. pneumoniae*, from clinical specimens obtained from sentinel sites spread throughout the Philippines.<sup>53</sup> These further emphasize the need for ESBL surveillance in the country considering that the antimicrobials used on ESBL-EC are rarely prescribed as first-line treatment against *E. coli* infections.<sup>16</sup>

### Carbapenemase-producing Carbapenem-resistant *E. coli*

In this study, all 24 *E. coli* isolates from chicken samples were susceptible to carbapenems, specifically, imipenem, meropenem, and ertapenem, and were therefore classified as non-CP-CREC. This is despite a local study in the Philippines which found 1.7% (2/117) and 19.2% (43/224) resistance rates against meropenem and imipenem, respectively, among *E. coli* isolates from chickens.<sup>14</sup> An international study also reported resistance rates of 17.8% (5/28) to meropenem and 28.0% (8/28) to imipenem from *E. coli* detected in internal organs of raw chickens in Pakistan.<sup>64</sup>

Nonetheless, the present investigation concurs with earlier research indicating that there are no reports of CP-CREC in poultry meat from wet markets in the Philippines. Similar to Egypt and the United Kingdom, there was also no evidence of CP-CREC isolated from retail chicken.<sup>60,65</sup> However, carbapenemases have been detected from *E. coli* isolated in the internal organs of chickens in Pakistan and in chicken cloacal swabs in Malaysia.<sup>64,66</sup> In addition, researchers in Egypt were also able to detect high rates of carbapenemases among other members of the Enterobacteriaceae family obtained from chicken meat.<sup>60</sup>

In addition, there are a number of potential sources of carbapenemase resistance genes that can transfer to bacteria present in poultry meat in wet markets. One study discovered CP-CREC in fish meat from a wet market in the Philippines.<sup>17</sup> Carbapenem resistance genes were also identified in a poultry broiler farm in Central Luzon.<sup>16</sup> The presence of these genes may be attributed to the origin and manner of transmission of antimicrobial residues, resistance genes, and resistant bacteria, such as those released into rivers.<sup>67</sup> It is possible that these potential sources of carbapenemase enzyme have not yet been transmitted in the samples used in this study due to differences in environmental exposure, sources of poultry meat, and livestock farm production practices.

Moreover, according to the 2021 DOH-ARSP report, there is also a statistically significant change in the annual resistance rate of carbapenems in *E. coli* such as imipenem, meropenem, and ertapenem in clinical isolates collected from sentinel locations in the Philippines.<sup>53</sup> Similarly, *E. coli* with the carbapenemase gene, commonly reported in clinical settings, was found in hospital sewage and river water in the

country.<sup>68</sup> Therefore, the existence of carbapenem resistance in the country facilitates the possible spread of these genes between humans, animals, and the environment, as highlighted in the One Health approach. This further necessitates active surveillance among the potential sources of resistance genes to prevent the emergence of carbapenem resistance as multiple studies in a variety of settings have demonstrated the spread of resistant genes and resistant bacteria among the community and the environment.<sup>69-71</sup> Carbapenems are also considered to be the last-resort antimicrobials<sup>72</sup>; hence, the proliferation of resistant microorganisms such as *E. coli* against this class of antimicrobials poses a hazard to public health and safety since it reduces the effectiveness of treating infections.

### One Health Approach

One Health acknowledges that human health is strongly associated with animal and environmental health.<sup>73</sup> Animals, albeit beneficial to humans in many ways, such as food and livelihood, can transmit diseases caused by AMR bacteria to humans.<sup>74</sup> Therefore, as human, animal, and animal product movement increase, diseases disperse more rapidly around the world.<sup>73</sup> The CDC also emphasizes that geographical boundaries cannot effectively prevent the spread of AMR; this is relevant to note in the context of this study as most of the retailed poultry in Manila City are grown from nearby areas like Central Luzon and CALABARZON.<sup>75</sup>

In animal food products, studies have revealed that the major sources of contamination are the environment, equipment, workers, and contaminated animal. Poor sanitation and hygiene practices favor the cross-contamination of animal food products like chicken meat with microorganisms. For instance, there is a high risk of contamination in retail stalls due to raw chicken drips that spread on other meat and contact surfaces.<sup>20</sup> Additionally, in the context of this research, most of the chicken retail stalls used wooden cutting boards and had tiled or plastic-covered table tops. It was observed that working surfaces have shown to be important in the proliferation of microbial pathogens. Wooden surfaces had the highest risk of ESBL-EC contamination, followed by tiled surfaces and plastic-sheet-covered surfaces, compared to stainless steel surfaces.<sup>20</sup> Also, cutting boards were found to play a role in ESBL-EC occurrence, wherein wooden cutting board was reported to have the highest risk and plastic cutting board was revealed to have twice the risk of contamination compared to stainless steel cutting instruments. Furthermore, the water source for handwashing and utensil cleaning may also be a possible source of contamination. It has been shown there is three times the risk of contamination when only one water container is used for both handwashing and cleaning of utensils during the retail period, as compared to directly using water from a tap source.<sup>20</sup> The sampling site in this study also displayed the raw chicken meat in an open area, which may also contribute to the profile of microorganisms that have been isolated.

## Limitations

One methodological limitation in this study was identified to be the usage of conventional methods for identification of isolates (i.e., the use of morphological and biochemical tests). In this study, the phenotypic isolation and identification of *E. coli* from raw chicken meat samples are prone to error because there are organisms that have similar biochemical characteristics to *E. coli*. It was observed that the characteristic green metallic sheen of *E. coli* on EMB plates may also be exhibited by other organisms, such as *Citrobacter*. Hence, there are potential risks of misidentification of the microorganism using morphological and biochemical parameters.

First, to increase the accuracy of identifying if the isolated organism is *E. coli*, multiple morphological and biochemical tests based on CLSI standards were performed. These biochemical tests include indole, methyl red, Voges Proskauer, and citrate (IMViC); oxidase; and triple sugar iron (TSI) tests. Triplicates and multiple subcultures of isolated samples were also conducted using EMB and MAC agar plates. Vigorous lactose-fermenting gram-negative bacteria create an acidic environment, which produces a green metallic sheen, characteristic of *E. coli*.<sup>76</sup> However, one sample had *E. coli*-like colonies on the EMB plate, which were later confirmed as *Citrobacter*, similar to one study that aimed to isolate *E. coli* from fresh vegetables.<sup>77</sup> Therefore, to confirm the identity of the isolates with green metallic sheen but with biochemical results that are inconsistent with *E. coli*, automated identification through VITEK MS was conducted to verify their identities at the Philippine General Hospital Department of Laboratories. This automated verification procedure decreased the risks of misidentification of the microorganisms.

Another methodological limitation identified was the phenotypic observation of AST and DDST. Both AST and DDST are heavily reliant on subjective interpretation of results, thus affecting the accuracy of the results.<sup>78</sup> To minimize errors, three to four researchers carried out the observation, microbiology experts were consulted to verify the findings, and control organisms were also used to verify DDST results.

Considering that the study only used chicken legs as the source of the specimen, microorganisms present in other parts of the chicken might have been missed out. To minimize this limitation, raw meat pieces were cut from different areas of the raw chicken leg.

## CONCLUSION

This study analyzed the AMR profile of *E. coli* isolated from raw chicken meat from retail stalls in a selected wet market in Manila City. Among the 25 chicken samples, 24 *E. coli* colonies were isolated while one was found to be *Citrobacter freundii*. The resistance rates to selected antimicrobial agents range from 0% to 92%. High resistance

rates were observed in ampicillin, tetracycline, trimethoprim-sulfamethoxazole, chloramphenicol, ampicillin-sulbactam, amoxicillin-clavulanic acid, fosfomycin, streptomycin, ciprofloxacin, and nalidixic acid, among others. However, there was no evidence of resistance to ceftriaxone, cefepime, or any of the carbapenems, including ertapenem, imipenem, and meropenem. Notably, most isolates (96%) were found to be resistant to at least one antimicrobial agent, with more than half (54%) exhibiting resistance to at least eight antimicrobial agents, and one isolate showing resistance to at least 14 antimicrobial agents.

Of the isolated *E. coli* colonies, 23 (96%) were classified as MDR, and none of the 24 isolated *E. coli* samples were considered ESBL- and CP-CR *E. coli*.

The findings of this study offer preliminary data that can serve as a foundation for a more comprehensive analysis of commercial chicken meat and surveillance of AMR in the country while taking into account the possibility of transmission between humans, animals, and the environment. The reported resistance rates among *E. coli* isolates from chicken meat could be used to support the development of more effective treatment strategies against critical MDR *E. coli* infections.

## Recommendations

The researchers recommend the use of automated techniques to improve the identification of *E. coli* as well as the characterization of its AMR profile. These technologies include, but are not limited to, the use of VITEK 2, VITEK MS, and PCR among others. To explore a broader antimicrobial profile, sensitivity against other antimicrobial agents can also be investigated. This can also determine possible extensively drug-resistant and pan drug-resistant microorganisms.

The researchers also suggest performing genotypic methods for future studies regarding ESBL and carbapenemase production. This could be done through PCR identification of the genes *bla*<sub>TEM</sub>, *bla*<sub>SHV</sub>, *bla*<sub>CTX-M</sub> and *bla*<sub>OXA</sub>, which are predominant among ESBL-producing *E. coli* in the country.<sup>14,16</sup>

Given the findings of this study, increased collaboration in addressing AMR in food products between various community sectors, including the academic community, government organizations, and food product handlers, can be promoted.

## Acknowledgment

The researchers would like to express their deepest gratitude to the Department of Science and Technology (DOST) that provided financial assistance for the implementation of the study.

## Statement of Authorship

All authors certified fulfillment of ICMJE authorship criteria.

## Author Disclosure

All authors declared no conflicts of interest.

## Funding Source

Financial assistance from the Department of Science and Technology - Science Education Institute for DOST Scholars.

## REFERENCES

- World Health Organization. Antimicrobial resistance [Internet]. Geneva, Switzerland: World Health Organization; 2021 Nov 17 [cited 2022]. Available from: <https://www.who.int/news-room/factsheets/detail/antimicrobial-resistance>
- Reygaert W. An overview of the antimicrobial resistance mechanisms of bacteria. *AIMS Microbiol.* 2018 June;4(3):482-501. doi:10.3934/microbiol.2018.3.482. PMID: 31294229; PMCID: PMC6604941.
- Arslan S, Eyi A. Antimicrobial resistance and ESBL prevalence in *Escherichia coli* from retail meats. *J. Food Saf.* 2011;31(2):262-267. doi:10.1111/j.1745-4565.2010.00295.x.
- Silago V, Kovacs D, Samson H, Seni J, Matthews L, Oravcová K, et al. Existence of multiple ESBL genes among phenotypically confirmed ESBL producing *Klebsiella pneumoniae* and *Escherichia coli* concurrently isolated from clinical, colonization and contamination samples from neonatal units at Bugando Medical Center, Mwanza, Tanzania. *Antibiotics.* 2021 April;10(5):467. doi:10.3390/antibiotics10050476. PMID: 33919117; PMCID: PMC8143173.
- Smith H, Kendall B. *Carbapenem Resistant Enterobacteriaceae* [Internet]. Treasure Island (FL): StatPearls Publishing; [updated 2023 Jan; cited 2022]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK551704/>
- Szmloka A, Nagy B. Multidrug resistant commensal *Escherichia coli* in animals and its impact for public health. *Front Microbiol.* 2013 Sep 3;4:258. doi:10.3389/fmicb.2013.00258. PMID: 24027562; PMCID: PMC3759790.
- Zhang S, Abbas M, Rehman M, Wang M, Jia R, Chen S, et al. Updates on the global dissemination of colistin-resistant *Escherichia coli*: an emerging threat to public health. *Sci. Total Environ.* 2021;799: 149280. doi:10.1016/j.scitotenv.2021.149280.
- Moawad A, Hotzel H, Neubauer H, Ehrlich R, Monecke S, Tomaso H, et al. Antimicrobial resistance in *Enterobacteriaceae* from healthy broilers in Egypt: emergence of colistin-resistant and extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli*. *Gut Pathog.* 2018 Sep;10(1). doi:10.1186/s13099-018-0266-5. PMID: 30250514; PMCID: PMC6148799.
- Aworh M, Kwaga J, Okolocha E, Mba N, Thakur S. Prevalence and risk factors for multi-drug resistant *Escherichia coli* among poultry workers in the Federal Capital Territory, Abuja, Nigeria. *PLoS One.* 2019 Nov;14(11):e0225379. doi:10.1371/journal.pone.0225379. PMID: 31751388; PMCID: PMC6872178.
- Urase T, Okazaki M, Tsutsui H. Prevalence of ESBL-producing *Escherichia coli* and carbapenem-resistant *Enterobacteriaceae* in treated wastewater: a comparison with nosocomial infection surveillance. *J Water Health.* 2020 Dec;18(6):899-910. doi:10.2166/wh.2020.014. PMID: 33328362.
- World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed [Internet]. Geneva, Switzerland: World Health Organization; 2017 Feb 27 [cited 2022]. Available from: <https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed>
- Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States 2019 [Internet]. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019 [cited 2022]. Available from: <https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf>
- de Guzman M, Manzano R, Monjardin, J. Antibiotic resistant bacteria in raw chicken meat sold in a public market in Quezon City, Philippines. *Philipp J Health Res Dev.* 2016;20(4):43-51.
- Belotindos L, Villanueva M, Miguel J, Jr, Bwalya P, Harada T, Kawahara R, et al. Prevalence and characterization of quinolone-resistance determinants in *Escherichia coli* isolated from food-producing animals and animal-derived food in the Philippines. *Antibiotics.* 2021 April;10(4):413. Available from: <https://doi.org/10.3390/antibiotics10040413>. PMID: 33918946; PMCID: PMC8068814.
- Vital P, Zara E, Paraoan C, Dimasupil M, Abello J, Santos I, et al. Antibiotic resistance and extended-spectrum beta-lactamase production of *Escherichia coli* isolated from irrigation waters in selected urban farms in Metro Manila, Philippines. *Water.* 2018 April;10(5):548. doi: 10.3390/w10050548.
- Gundran R, Cardenio P, Villanueva M, Sison F, Benigno C, Kreausukon K, et al. Prevalence and distribution of blaCTX-M, blaSHV, blaTEM genes in extended-spectrum  $\beta$ -lactamase-producing *E. coli* isolates from broiler farms in the Philippines. *BMC Vet. Res.* 2019 Jul;15(1):227. doi: 10.1186/s12917-019-1975-9. PMID: 31277658; PMCID: PMC6612079.
- Kang T, Oyong G, Cabrera E. High prevalence of carbapenem and extended spectrum  $\beta$ -lactam resistant *Escherichia coli* from tilapia (*Oreochromis niloticus*) from two wet markets in Metro Manila, Philippines. *Malays. J. Microbiol.* 2020;16(2):88-96. doi:10.21161/mjm.180304
- Philippine Statistics Authority. Highlights of the population density of the Philippines 2020 census of population and housing (2020 CPH) [Internet]. Quezon City (PH): Philippine Statistics Authority; 2021 July 23 [cited 2022]. Available from: <https://psa.gov.ph/content/highlights-population-density-philippines-2020-census-population-and-housing-2020-cph>
- Parvin M, Talukder S, Ali M, Chowdhury E, Rahman M, Islam M. Antimicrobial resistance pattern of *Escherichia coli* isolated from frozen chicken meat in Bangladesh. *Pathogens.* 2020 May;9(6):420. doi: 10.3390/pathogens9060420. PMID: 32481680; PMCID: PMC7350304.
- Aliyu A, Saleha A, Jalila A, Zunita Z. Risk factors and spatial distribution of extended spectrum  $\beta$ -lactamase-producing *Escherichia coli* at retail poultry meat markets in Malaysia: a cross-sectional study. *BMC Public Health.* 2016 Aug;16(699). doi: 10.1186/s12889-016-3377-2.
- Brooks G, Carroll K, Butel J, Morse, S, editors. *Jawetz, Melnick & Adelberg's Medical Microbiology.* 24th ed. McGraw Hill; 2007. pp. 229-241.
- Mahon CR, Lehman DC, Manuselis G. *Textbook of Diagnostic Microbiology.* 5th ed. Elsevier; 2015. pp. 421-454.
- Tille P. *Bailey & Scott's Diagnostic Microbiology.* 14th ed. Mosby; 2016. pp. 307-327.
- ThermoFisher Scientific. Storing bacterial samples for optimal viability [Internet]. [cited 2022]. Available from: [https://www.thermofisher.com/nl/en/home/industrial/microbiology/microbiology-learning-center/storing-bacterial-samples-optimal-viability.html#:~:text=Bacterial%20cultures%20that%20are%20used,bacterial%20viability%20\(Table%201\)](https://www.thermofisher.com/nl/en/home/industrial/microbiology/microbiology-learning-center/storing-bacterial-samples-optimal-viability.html#:~:text=Bacterial%20cultures%20that%20are%20used,bacterial%20viability%20(Table%201)).
- Hudzicki J. Kirby-Bauer disk diffusion susceptibility test protocol [Internet]. American Society for Microbiology. 2009 Dec [cited 2022]. Available from: <https://asm.org/getattachment/2594ce26-bd44-47f6-8287-0657aa9185ad/Kirby-Bauer-Disk-Diffusion-Susceptibility-Test-Protocol-pdf>
- Kaur J, Chopra S, Sheevani, Mahajan, G. Modified double disc synergy test to detect ESBL production in urinary isolates of *Escherichia coli* and *Klebsiella pneumoniae*. *J Clin Diagnostic Res.* 2013;7(2):229-33. doi: 10.7860/JCDR/2013/4619.2734. PMID: 23543257; PMCID: PMC3592280.
- Cruz M, Bacani C, Mendoza A, Hedreya C. Evaluation of extended-spectrum beta-lactamase production in *Escherichia coli* clinical isolates from three hospitals in Luzon, Philippines. *Philippine Science Letters.* 2014;7:438-444.

28. Clinical and Laboratory Standards Institute. CLSI supplement M100: Performance standards for antimicrobial susceptibility testing [Internet]. 30th ed. 2020 [cited 2022]. Available from: <https://www.nih.org.pk/wp-content/uploads/2021/02/CLSI-2020.pdf>
29. Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012;18(3):268-281. doi: 10.1111/j.1469-0691.2011.03570.x. PMID: 21793988.
30. de Mesquita Souza Saraiva M, Lim K, do Monte D, Givisiez P, Alves L, de Freitas Neto O, et al. Antimicrobial resistance in the globalized food chain: A One Health perspective applied to the poultry industry. *Braz J Microbiol*. 2022 Mar;53(1): 465-86. doi: 10.1007/s42770-021-00635-8. PMID: 34775576; PMCID: PMC8590523.
31. Founou L, Founou R, Essack S. Antimicrobial resistance in the farm-to-plate continuum: More than a food safety issue. *Future Sci OA*. 2021 Jun;7(5):FSO692. doi: 10.2144/fsoa-2020-0189. PMID: 34046194; PMCID: PMC8147750.
32. World Health Organization. Integrated Surveillance of Antimicrobial Resistance in Foodborne Bacteria: Application of a One Health Approach [Internet]. 2017 [cited 2022]. Available from: <https://apps.who.int/iris/bitstream/handle/10665/255747/9789241512411-eng.pdf>
33. Nhung N, Chansiripornchai N, Carrique-Mas J. Antimicrobial resistance in bacterial poultry pathogens: A review. *Front Vet Sci*. 2017;4:126. doi: 10.3389/fvets.2017.00126. PMID: 28848739; PMCID: PMC5554362.
34. Stromberg Z, Johnson J, Fairbrother J, Kilbourne J, Van Goor A, Curtiss R, et al. Evaluation of *Escherichia coli* isolates from healthy chickens to determine their potential risk to poultry and human health. *PLoS One*. 2017;12(7). doi: 10.1371/journal.pone.0180599. PMID: 28671990; PMCID: PMC5495491.
35. Elumba Z, Allera M, Taganas R. Occurrence and Antibiotic Sensitivity of *Escherichia coli* and *Salmonella* spp. in retail chicken meat at selected markets in Valencia City, Bukidnon, Philippines. *Asian J. Biol. Sci*. 2018;7(2):53. doi: 10.5530/ajbls.2018.7.4
36. Torio H, Padilla M. Multiple resistance to medically important antimicrobials of commensal *Escherichia coli* isolated from dressed broiler chickens in Calabarzon, Philippines. *Philipp. J. Vet. Med*. 2018;55(2):95-106.
37. Davis G, Waits K, Nordstrom L, Grande H, Weaver B, Papp K, et al. Antibiotic-resistant *Escherichia coli* from retail poultry meat with different antibiotic use claims. *BMC Microbiol*. 2018;18(1): 174. doi: 10.1186/s12866-018-1322-5. PMID: 30390618; PMCID: PMC6215666.
38. Wu Q, Xi M, Lv X, Xu Y, Feng Y, Li Q, et al. Presence and antimicrobial susceptibility of *Escherichia coli* recovered from retail chicken in China. *J Food Prot*. 2014;77(10):1773-7. doi: 10.4315/0362-028X.JFP-14-080. PMID: 25285496.
39. Odwar J, Kikuyi G, Kariuki J, Kariuki S. A cross-sectional study on the microbiological quality and safety of raw chicken meats sold in Nairobi, Kenya. *BMC Res. Notes*. 2014;7(1):627. doi: 10.1186/1756-0500-7-627
40. Ghodousi A, Bonura C, Di Noto A, Mammina C. Extended-spectrum  $\beta$ -lactamase, AmpC-producing, and fluoroquinolone-resistant *Escherichia coli* in retail broiler chicken meat, Italy. *Foodborne Pathog Dis*. 2015;12(7):619-25. doi: 10.1089/fpd.2015.1936. PMID: 26135894.
41. Yulistiani R, Praseptianga D, Supyani, Sudibya, Raharjo, D, Shirakawa T. Prevalence of antibiotic-resistance Enterobacteriaceae strains isolated from chicken meat at traditional markets in Surabaya, Indonesia. *IOP Conference Series: Materials Science and Engineering*. 2017 April;193(1):012007. doi: 10.1088/1757-899X/193/1/012007.
42. Rahman MA, Rahman AKMA, Islam MA, Alam, MM. Antimicrobial resistance of *Escherichia coli* isolated from milk, beef and chicken meat In Bangladesh. *Bangladesh Journal of Veterinary Medicine*. 2018 Jan;15(2):141. doi: 10.3329/bjvm.v15i2.35525.
43. Eltai NO, Yassine HM, El-Obeid T, Al-Hadidi SH, Al Thani AA, Alali WQ. Prevalence of antibiotic-resistant *Escherichia coli* isolates from local and imported retail chicken carcasses. *J Food Prot*. 2020 Dec; 83(12):2200-8. doi: 10.4315/JFP-20-113. PMID: 32730573.
44. Phiri N, Mainda G, Mukuma M, Sinyangwe NN, Banda LJ, Kwenda G, et al. Antibiotic-resistant *Salmonella* species and *Escherichia coli* in broiler chickens from farms, abattoirs, and open markets in selected districts of Zambia. *Journal of Epidemiological Research* [Internet]. 2020 Sep;6(1):13. doi: 10.5430/jer.v6n1p13.
45. Jiao SC, Fami RL, Pederal VD, Cabrera EC. Prevalence of multiple drug-resistant *Escherichia coli* from chicken, pig and Nile tilapia (*Oreochromis nilotica*) intestines sold in wet markets in Manila and the conjugative transferability of the resistance. *Philipp. Agric. Sci*. 2007 Mar;90(1):64-70.
46. Barroga TR, Morales RG, Benigno CC, Castro SJ, Caniban MM, Cabullo MF, et al. Antimicrobials used in backyard and commercial poultry and swine farms in the Philippines: A qualitative pilot study. *Front Vet Sci*. 2020 Jul;7:329. doi: 10.3389/fvets.2020.00329. PMID: 32733922; PMCID: PMC7360799.
47. Imperial IC, Pabustan PM, Valencia KA, Nicdao MA, Ibana J. Emergence of resistance genes in fecal samples of antibiotic-treated Philippine broilers emphasizes the need to review local farming practices. *Trop Biomed*. 2022 Mar;39(1):150-9. doi: 10.47665/tb.39.1.020. PMID: 35507938
48. Agero Y, Bager F, Boel J, Helwigh B, Hog BB, Jensen LB, et al. DANMAP 2013 (Danish Integrated Antimicrobial Resistance Monitoring and Research Programme). Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. *DTU Orbit* [Internet]. 2014 Sep [cited 2022]. Available from: <https://orbit.dtu.dk/en/publications/danmap-2013-use-of-antimicrobial-agents-and-occurrence-of-antimic>
49. Jiménez-Belenguer A, Doménech E, Villagrà A, Fenollar A, Ferrús MA. Antimicrobial resistance of *Escherichia coli* isolated in newly-hatched chickens and effect of amoxicillin treatment during their growth. *Avian Pathol*. [Internet]. 2016 Aug;45(4):501-50. doi: 10.1080/03079457.2016.1168515x. PMID: 27035748.
50. World Health Organization. Philippines: The Philippine action plan to combat antimicrobial resistance: A one health approach [Internet]. Geneva, Switzerland: World Health Organization; 2019 January 2 [cited 2022]. Available from: <https://www.who.int/publications/m/item/philippines-the-philippine-action-plan-to-combat-antimicrobial-resistance-one-health-approach>
51. Sunde M, Norström M. The prevalence of, associations between and conjugal transfer of antibiotic resistance genes in *Escherichia coli* isolated from Norwegian meat and meat products. *J Antimicrob Chemother*. 2006 Oct;58(4):741-7. doi: 10.1093/jac/dkl294. PMID: 16931539.
52. Department of Agriculture and Department of Health. Declaring a ban on the use of chloramphenicol in food producing animals: Department of Agriculture Administrative Order No. 60, Series of 1990; Department of Health Administrative Order No. 91, Series of 1990 [Internet]. Manila, Philippines: Department of Agriculture and Department of Health; 1990 April 30 [cited 2022]. Available from: <https://www.fda.gov.ph/wp-content/uploads/2021/04/Administrative-Order-No.-91-s.-1990.pdf>
53. Department of Health. ARSP 2021 annual report data summary. Antimicrobial Resistance Surveillance Program [Internet]. Manila, Philippines: Department of Health; 2022 [cited 2022]. Available from: <https://arsp.com.ph/publications/>
54. McEwen SA, Collignon PJ. Antimicrobial resistance: A one health perspective. *Microbiol Spectr*. 2018 Mar;6(2). doi: 10.1128/microbiolspec.arba-0009-2017. PMID: 29600770.
55. Numanovic F, Hukic M, Delibegovic Z, Tihic, Nijaz, Pasic S, et al. Comparison of double disk synergy test, VITEK 2 and Check-MDR CT102 for detection of ESBL producing isolates. *Acta Med Acad*. 2013 May;42(1):15-24. doi: 10.5644/ama2006-124.66. PMID: 23735062.
56. Belotindos L. Characteristics of *Escherichia coli* isolated from livestock and related materials in the Philippines. Hokkaido University

- Collection of Scholarly and Academic Papers [Internet]. 2021 Sep [cited 2022]. doi: 10.14943/doctoral.k14719.
57. Wang J, Stephan R, Karczmarczyk M, Yan Q, Hächler H, Fanning S. Molecular characterization of blaESBL-harboring conjugative plasmids identified in multi-drug resistant *Escherichia coli* isolated from food-producing animals and healthy humans. *Front Microbiol*. 2013 Jul;4:188. doi: 10.3389/fmicb.2013.00188. PMID: 23874325; PMCID: PMC3708134.
  58. Effendi MH, Tyasningsih W, Yurianti YA, Rahmahani J, Harijani N, Plumeriastuti H. Presence of multidrug resistance (MDR) and extended-spectrum beta-lactamase (ESBL) of *Escherichia coli* isolated from cloacal swab of broilers in several wet markets in Surabaya, Indonesia. *Biodiversitas*. 2021 Jan;22(1):304-10. doi: 10.13057/biodiv/d220137.
  59. Overdeest I, Willemsen I, Rijnsburger M, Eustac A, Xu L, Hawkey P, et al. Extended-spectrum  $\beta$ -lactamase genes of *Escherichia coli* in chicken meat and humans, The Netherlands. *Emerg Infect Dis*. 2011 Jul;17(7):1216-22. doi: 10.3201/eid1707.110209. PMID: 21762575; PMCID: PMC3381403.
  60. Abdallah H, Reuland EA, Wintermans BB, Al Naiemi N, Koek A, Abdelwahab AM, et al. Extended-spectrum  $\beta$ -lactamases and/or carbapenemases-producing Enterobacteriaceae isolated from retail chicken meat in Zagazig, Egypt. *PLoS One*. 2015 Aug 18;10(8):e0136052-2. doi: 10.1371/journal.pone.0136052. PMID: 26284654; PMCID: PMC4540287.
  61. Nadimpalli M, Vuthy Y, de Lauzanne A, Fabre L, Criscuolo A, Gouali M, et al. Meat and fish as sources of Extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli*, Cambodia. *Emerg Infect Dis*. 2019;25(1):126-31. doi: 10.3201/eid2501.180534. PMID: 30561323; PMCID: PMC6302604.
  62. Murray MJ, Salvatierra G, Dávila-Barclay A, Ayzanoa B, Castillo-Vilcahuaman C, Huang M, et al. Market chickens as a source of antibiotic-resistant *Escherichia coli* in a peri-urban community in Lima, Peru. *Front Microbiol*. 2021 Mar 2;12. doi: 10.3389/fmicb.2021.635871. PMID: 33737922; PMCID: PMC7961087.
  63. Miranda I, Ignatius R, Pfüller R, Friedrich-Jänicke B, Steiner FM, Paland M, et al. High carriage rate of ESBL-producing Enterobacteriaceae at presentation and follow-up among travellers with gastrointestinal complaints returning from India and Southeast Asia. *J Travel Med*. 2016 Feb 1;23(2):tav024-4. doi: 10.1093/jtm/tav024. PMID: 26858272.
  64. Younas M. Multidrug resistant carbapenemase-producing *Escherichia coli* from chicken meat reveals diversity and co-existence of carbapenemase encoding genes. *Pak. Vet. J*. 2019 Apr 1;39(02):241-5. doi: 10.29261/pakvetj/2019.047.
  65. Randall LP, Lodge MP, Elviss N, Lemma F, Hopkins KL, Teale C, et al. Evaluation of meat, fruit and vegetables from retail stores in five United Kingdom regions as sources of extended-spectrum beta-lactamase (ESBL)-producing and carbapenem-resistant *Escherichia coli*. *Int J Food Microbiol*. 2017 Jan 1;241:283-90. doi: 10.1016/j.ijfoodmicro.2016.10.036; PMID: 27821357.
  66. Erkihun A, Harun A, Singh KKB, Ibrahim S, Kamaruzzaman NF. Phylogenetically diverse *Escherichia coli* strains from chicken coharbor multiple carbapenemase-encoding genes (blaNDM-blaOXA-blaIMP). *Biomed Res Int*. 2021 Oct 6;2021:1-7. doi: 10.1155/2021/5596502. PMID: 34660793; PMCID: PMC8514898.
  67. Sun Q, Wang Y, Hulth A, Xiao Y, Nilsson L, Li X, et al. Study protocol for One Health data collections, analyses and intervention of the Sino-Swedish integrated multisectoral partnership for antibiotic resistance containment (IMPACT). *BMJ Open*. 2018 Jan 1;8(1):e017832-2. doi: 10.1136/bmjopen-2017-017832. PMID: 29358424; PMCID: PMC5780695.
  68. Suzuki Y, Nazareno PJ, Nakano R, Mondoy M, Nakano A, Bugayong MP, et al. Environmental presence and genetic characteristics of carbapenemase-producing Enterobacteriaceae from hospital sewage and river water in the Philippines. *Appl Environ Microbiol*. 2019. doi: 10.1128/AEM.01906-19. PMID: 31704681; PMCID: PMC6952235.
  69. Cabal A, Rab G, Daza-Prieto B, Stöger A, Peischl N, Chakeri A, et al. Characterizing antimicrobial resistance in clinically relevant bacteria isolated at the human/animal/environment interface using whole-genome sequencing in Austria. *Int J Mol Sci*. 2022 Sep 24;23(19):11276-6. doi: 10.3390/ijms231911276. PMID: 36232576; PMCID: PMC9570485.
  70. Li J, Bi Z, Ma S, Chen B, Cai C, He J, et al. Inter-host transmission of carbapenemase-producing *Escherichia coli* among humans and backyard animals. *Environ Health Perspect*. 2019 Oct;127(10):107009. doi: 10.1289/EHP5251. PMID: 31642700; PMCID: PMC6910777.
  71. Mandal AKJ, Talukder S, Hasan M, Tasmim ST, Parvin MS, Ali MY. Epidemiology and antimicrobial resistance of *Escherichia coli* in broiler chickens, farmworkers, and farm sewage in Bangladesh. *Vet Med Sci*. 2021 Nov 2;8(1):187-99. doi: 10.1002/vms3.664. PMID: 34729951; PMCID: PMC8788966.
  72. Torres JP, Maria Virginia Villegas, Quinn JP. Current concepts in antibiotic-resistant Gram-negative bacteria. *Expert Rev Anti Infect Ther*. 2007 Oct 1;5(5):833-43. doi: 10.1586/14787210.5.5.833. PMID: 17914917.
  73. Centers for Disease Control and Prevention. One Health Basics [Internet]. 2022 [cited 2022]. Available from: <https://www.cdc.gov/onehealth/basics/index.html>
  74. Pokharel S, Shrestha P, Adhikari B. Antimicrobial use in food animals and human health: time to implement “One Health” approach. *Antimicrob Resist Infect Control*. 2020 Nov 7;9(1). doi: 10.1186/s13756-020-00847-x. PMID: 33160396; PMCID: PMC7648983.
  75. Philippine Statistics Authority | Republic of the Philippines [Internet]. 2013 [cited 2022]. Available from: <https://psa.gov.ph/livestock-poultry-ipers/chicken>
  76. Lal A, Cheeptham N. Eosin-Methylene Blue Agar Plates Protocol [Internet]. American Society for Microbiology; 2007 Sep [cited 2022]. Available from: <https://asm.org/ASM/media/Protocol-Images/Eosin-Methylene-Blue-Agar-Plates-Protocol.pdf?ext=.pdf>
  77. Kim HS, Kim YJ, Chon JW, Kim DH, Kim KY, Kim H. Citrobacter braakii: A major cause of false-positive results on MacConkey and Levine's eosin methylene blue selective agars used for the isolation of *Escherichia coli* from fresh vegetable samples. *J Food Saf*. 2015 Jul 15;36(1):33-7. doi: 10.1111/jfs.12210.
  78. Rawat D, Nair D. Extended-spectrum  $\beta$ -lactamases in Gram-negative bacteria. *J Glob Infect Dis*. 2010 Jan 1;2(3):263-3. doi: 10.4103/0974-777X.68531. PMID: 20927289; PMCID: PMC2946684.

## APPENDICES

Appendix Table 1. Zone Diameter Breakpoints for Enterobacteriaceae (CLSI, 2020)

Test /Report Group	Antimicrobial Agent	Disk Content	Interpretative Categories and Zone Diameter Breakpoints, nearest whole mm			
			S	SDD	I	R
<b>Aminoglycosides</b>						
O	Streptomycin	10 µg	≥15	-	12-14	≤11
<b>Antipseudomonal Penicillin with beta-lactamase inhibitors</b>						
B	Piperacillin-Tazobactam	100/10 µg	≥21	-	18-20	≤17
<b>Carbapenems</b>						
B	Ertapenem	10 µg	≥22	-	19-21	≤18
B	Imipenem	10 µg	≥23	-	20-22	≤19
B	Meropenem	10 µg	≥23	-	20-22	≤19
<b>Non-extended spectrum cephalosporins</b>						
A	Cefazolin	30 µg	≥23	-	20-22	≤19
B	Cefuroxime	30 µg	≥18	-	15-17	≤14
<b>Extended spectrum cephalosporins</b>						
B	Cefotaxime	30 µg	≥26	-	23-25	≤22
B	Ceftriaxone	30 µg	≥23	-	20-22	≤19
C	Ceftazidime	30 µg	≥21	-	18-20	≤17
B	Cefepime	30 µg	≥25	-	19-24	≤18
<b>Cephameycins</b>						
B	Cefoxitin	30 µg	≥18	-	15-17	≤14
<b>Fluoroquinolones</b>						
B	Ciprofloxacin	5 µg	≥26	-	22-25	≤21
<b>Quinolones</b>						
O	Nalidixic acid	30 µg	≥19	-	14-18	≤13
<b>Folate Pathway Inhibitors</b>						
B	Trimethoprim-sulfamethoxazole	1.25/23.75 µg	≥16	-	11-15	≤10
<b>Monobactams</b>						
C	Aztreonam	30 µg	≥21	-	18-20	≤17
<b>Penicillins</b>						
A	Ampicillin	10 µg	≥17	-	14-16	≤13
<b>Penicillins with beta-lactamase inhibitors</b>						
B	Amoxicillin-clavulanate	20/10 µg	≥18	-	14-17	≤13
B	Ampicillin-sulbactam	10/10 µg	≥15	-	12-14	≤11
<b>Phenicol</b>						
C	Chloramphenicol	30 µg	≥18	-	13-17	≤12
<b>Phosphonic Acids</b>						
U	Fosfomycin	200 µg	≥16	-	13-15	≤12
<b>Tetracyclines</b>						
C	Tetracycline	30 µg	≥15	-	12-14	≤11
<b>Nitrofurantoin</b>						
U	Nitrofurantoin	300 µg	≥17	-	15-16	≤14

Appendix Table 2. Proportion of susceptible, intermediate, and resistant *E. coli* isolates isolated from raw chicken meat samples (n = 24)

	Antimicrobial Agent	<i>E. coli</i> isolates tested, n (%)					
		Susceptible		Intermediate		Resistant	
<b>Aminoglycosides</b>	STR	1	4%	10	42%	13	54%
<b>Antipseudomonal Penicillin with beta-lactamase inhibitors</b>	TZP	23	96%	1	4%	0	0%
<b>Carbapenems</b>	ETP	24	100%	0	0%	0	0%
	IPM	24	100%	0	0%	0	0%
	MEM	24	100%	0	0%	0	0%
<b>Non-extended spectrum cephalosporins</b>	CFZ	4	17%	19	79%	1	4%
	CXM	23	96%	1	4%	0	0%
<b>Extended spectrum cephalosporins</b>	CTX	23	96%	0	0%	1	4%
	CRO	24	100%	0	0%	0	0%
	CAZ	23	96%	0	0%	1	4%
	FEP	24	100%	0	0%	0	0%
<b>Cephameycins</b>	FOX	22	92%	1	4%	1	4%
<b>Fluoroquinolones</b>	CIP	2	8%	12	50%	10	42%
<b>Quinolone</b>	NAL	12	50%	4	17%	8	33%
<b>Folate pathway inhibitors</b>	SXT	4	17%	0	0%	20	83%
<b>Monobactams</b>	ATM	23	96%	0	0%	1	4%
<b>Penicillins</b>	AMP	1	4%	1	4%	22	92%
<b>Penicillins with beta-lactamase inhibitors</b>	AMC	2	8%	6	25%	16	67%
	SAM	5	21%	1	4%	18	75%
<b>Phenicol</b>	CHL	4	17%	1	4%	19	79%
<b>Phosphonic acids</b>	FOF	8	33%	0	0%	16	67%
<b>Tetracyclines</b>	TET	1	4%	2	8%	21	88%
<b>Nitrofurantoin</b>	NIT	20	83%	0	0%	4	17%

Appendix Table 3. ZOI per antimicrobial agent of each isolate

Isolate (Stall Code-Isolate No.)	Antimicrobial Class																						
	Amino glycosides	Antipseudomonal Penicillin with Beta-Lactamase Inhibitors		Carbapenem			Non-extended Spectrum Cephalosporins			Extended Spectrum Cephalosporins			Cephameycin	Fluoroquinolones	Quinolone	Folate Pathway Inhibitors	Monobactam	Penicillin	Penicillins with beta-lactamase inhibitors	Phenicol	Phosphonic Acids	Tetracycline	Nitrofurantoin
	STR	TZP	ETP	IPM	MEM	CFZ	CXM	CTX	CRO	CAZ	FEP	FOX	CIP	NAL	SXT	ATM	AMP	AMC	SAM	CHL	FOF	TET	NIT
Control	19	31	32	31	35	29	29	32	33	29	35	30	28	28	35	17	24	21	30	31	31	23	
A-3	6	25	30	32	31	23	23	26	29	21	28	20	10	6	6	12	6	17	18	7	18	14	17
B-2	6	21	27	29	29	20	20	28	27	23	26	20	14	6	6	28	6	12	9	8	6	6	14
C-1	13	25	27	29	29	25	24	30	29	25	29	29	23	21	26	32	14	23	23	25	35	11	22
D-3	15	25	27	30	30	24	24	30	30	27	30	22	29	24	26	32	20	22	19	32	33	12	21
E-2	11	26	26	28	29	21	23	27	28	24	28	21	17	6	6	30	6	14	11	8	27	6	20
F-2	6	22	28	28	29	21	23	29	27	25	28	24	23	18	6	31	6	10	8	6	6	99	20
G-2	14	23	28	28	30	20	21	30	29	24	30	28	25	22	6	30	6	15	13	6	6	7	21
H-2	14	23	28	25	28	19	23	30	28	24	29	22	27	20	6	29	6	10	9	8	6	6	19
I-3	14	24	28	27	30	23	21	28	26	23	27	22	9	6	6	28	6	10	9	6	6	6	20
J-1	11	21	27	29	30	22	22	30	29	24	29	22	23	19	6	30	6	11	7	7	6	9	17
K-3	12	20	28	29	31	22	23	29	28	25	27	24	6	6	6	30	6	10	7	6	6	6	17
L-3	11	23	26	28	28	22	23	30	30	24	30	25	22	21	6	30	6	16	16	24	25	25	14
M-1	10	21	30	29	31	21	22	30	26	25	28	22	22	19	6	29	6	12	8	6	6	6	22
N-1	NOT <i>E. coli</i> (Bacteria identified: <i>Citrobacter freundii</i> )																						
O-3	6	22	28	28	30	21	22	27	28	24	28	24	12	6	6	31	6	12	9	6	6	6	21
P-2	11	23	29	27	29	22	22	29	29	23	29	24	22	19	6	30	6	9	6	6	6	6	17
Q-2	10	24	28	31	31	21	22	29	28	29	23	23	23	21	22	30	6	14	11	6	26	6	18
R-1	6	21	27	28	30	20	19	27	26	22	26	17	18	16	6	29	6	10	9	6	6	6	20
S-2	13	22	29	28	29	21	20	28	27	23	25	24	24	21	6	28	6	13	9	6	6	6	20
T-1	12	23	28	30	30	21	23	31	28	25	31	24	24	23	6	30	6	12	11	15	6	9	19
U-2	9	23	23	23	30	11	16	22	23	15	26	6	21	17	6	25	6	9	10	10	6	6	6
V-3	12	23	28	29	30	21	19	28	28	23	30	20	6	6	6	27	6	12	10	8	6	6	19
W-3	13	21	27	28	29	21	22	30	29	24	29	21	11	6	23	30	6	13	11	10	27	11	14
X-2	12	22	28	30	30	22	22	30	29	29	22	22	22	22	6	31	6	11	10	10	6	6	19
Y-1	9	24	26	28	28	20	21	28	27	23	28	21	22	18	6	29	6	16	15	24	29	6	19

STR - Streptomycin; TZP - Piperacillin-Tazobactam; ETP - Ertapenem; IPM - Imipenem; MEM - Meropenem; CFZ - Cefazolin; CXM - Cefuroxime; CTX - Cefotaxime; CRO - Ceftriaxone; CAZ - Ceftazidime; FEP - Cefepime; FOX - Cefoxitin; CIP - Ciprofloxacin; NAL - Nalidixic acid; SXT - Trimethoprim-sulfamethoxazole; ATM - Aztreonam; AMP - Ampicillin; AMC - Amoxicillin-clavulanate; SAM - Ampicillin-sulbactam; CHL - Chloramphenicol; FOF - Fosfomicin; TET - Tetracycline. Red-colored cells are resistant, blue-colored cells are intermediate, and yellow-colored cells are susceptible.